Prevention and treatment of COVID-19 by mono- and poly-clonal antibodies.
作者信息
McIntosh David, Burnouf Thierry, Karbiener Michael, Farcet Maria R, Kreil Thomas R
机构信息
UK Plasma Action, Petersfield, United Kingdom.
Graduate Institute of Biomedical Materials and Tissue Engineering, College of Biomedical Engineering, Taipei Medical University, Taipei, Taiwan.
出版信息
Blood Transfus. 2023 Sep;21(5):375-377. doi: 10.2450/BloodTransfus.436. Epub 2023 Feb 24.
Abstract
摘要
相似文献
1
Prevention and treatment of COVID-19 by mono- and poly-clonal antibodies.单克隆抗体和多克隆抗体对新型冠状病毒肺炎的预防与治疗
Blood Transfus. 2023 Sep;21(5):375-377. doi: 10.2450/BloodTransfus.436. Epub 2023 Feb 24.
2
Audio Interview: Monoclonal Antibodies and Vaccine Boosts.音频访谈：单克隆抗体与疫苗加强针
N Engl J Med. 2021 Jul 15;385(3):e18. doi: 10.1056/NEJMe2111903.
3
Update on and Future Directions for Use of Anti-SARS-CoV-2 Antibodies: National Institutes of Health Summit on Treatment and Prevention of COVID-19.抗 SARS-CoV-2 抗体的最新进展及未来应用方向：NIH 新冠肺炎治疗和预防峰会。
Ann Intern Med. 2022 Jan;175(1):119-126. doi: 10.7326/M21-3669. Epub 2021 Nov 2.
4
Audio Interview: Planning for the SARS-CoV-2 Vaccine Rollout.音频访谈：SARS-CoV-2疫苗接种计划
N Engl J Med. 2021 Jan 7;384(1):e13. doi: 10.1056/NEJMe2100295.
5
Audio Interview: Aspects of Covid-19 Immunity.音频访谈：新冠病毒免疫力的相关方面
N Engl J Med. 2021 Aug 19;385(8):e31. doi: 10.1056/NEJMe2113747.
6
Safety and Tolerability of Monoclonal Antibody Therapies for Treatment of COVID-19 in Pediatric Patients.COVID-19 儿科患者单抗治疗的安全性和耐受性。
Pediatr Infect Dis J. 2021 Dec 1;40(12):e507-e509. doi: 10.1097/INF.0000000000003263.
7
Clinical Prioritization of Antispike Monoclonal Antibody Treatment of Mild to Moderate COVID-19.轻至中度新冠肺炎抗刺突单克隆抗体治疗的临床优先级
Mayo Clin Proc. 2022 Jan;97(1):26-30. doi: 10.1016/j.mayocp.2021.11.017. Epub 2021 Nov 19.
8
Audio Interview: Covid-19 and the Media.音频访谈：新冠疫情与媒体
N Engl J Med. 2021 Sep 30;385(14):e59. doi: 10.1056/NEJMe2115825.
9
COVID-19 global pandemic: vaccines and new monoclonal antibodies, aspects to be clarified.新型冠状病毒肺炎全球大流行：疫苗与新型单克隆抗体，有待阐明的方面。
Immunol Res. 2021 Apr;69(2):115-116. doi: 10.1007/s12026-021-09193-5. Epub 2021 Apr 15.
10
Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7.SARS-CoV-2 变体 B.1.351 和 B.1.1.7 的抗体抗性。
Nature. 2021 May;593(7857):130-135. doi: 10.1038/s41586-021-03398-2. Epub 2021 Mar 8.
本文引用的文献
1
Convalescent plasma and COVID-19: Time for a second-second look?恢复期血浆与 COVID-19：是否需要重新审视？
Transfus Med. 2023 Feb;33(1):16-20. doi: 10.1111/tme.12915. Epub 2022 Sep 11.
2
Omicron Severe Acute Respiratory Syndrome Coronavirus 2 Neutralization by Immunoglobulin Preparations Manufactured From Plasma Collected in the United States and Europe.Omicron 严重急性呼吸综合征冠状病毒 2 中和作用由从美国和欧洲采集的血浆制成的免疫球蛋白制剂产生。
J Infect Dis. 2022 Oct 17;226(8):1396-1400. doi: 10.1093/infdis/jiac358.
3
Hyperimmune Globulin for Severely Immunocompromised Patients Hospitalized With Coronavirus Disease 2019: A Randomized, Controlled Trial.特免球蛋白治疗 2019 冠状病毒病住院严重免疫功能低下患者：一项随机对照试验。
J Infect Dis. 2023 Jan 11;227(2):206-210. doi: 10.1093/infdis/jiac334.
4
Hyperimmune immunoglobulin for hospitalised patients with COVID-19 (ITAC): a double-blind, placebo-controlled, phase 3, randomised trial.COVID-19 住院患者的免疫球蛋白（ITAC）：一项双盲、安慰剂对照、3 期、随机试验。
Lancet. 2022 Feb 5;399(10324):530-540. doi: 10.1016/S0140-6736(22)00101-5. Epub 2022 Jan 28.
5
B and T cell response to SARS-CoV-2 vaccination in health care professionals with and without previous COVID-19.医护人员中有无既往 COVID-19 史者对 SARS-CoV-2 疫苗接种的 B 和 T 细胞应答。
EBioMedicine. 2021 Aug;70:103539. doi: 10.1016/j.ebiom.2021.103539. Epub 2021 Aug 12.
Zotero 插件